Novel Therapies for BioFilm-Related Infections

Information

  • Research Project
  • 6690432
  • ApplicationId
    6690432
  • Core Project Number
    R44AI054018
  • Full Project Number
    1R44AI054018-01A1
  • Serial Number
    54018
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/2003 - 20 years ago
  • Project End Date
    10/31/2003 - 20 years ago
  • Program Officer Name
    MOSHELL, ALAN N.
  • Budget Start Date
    8/1/2003 - 20 years ago
  • Budget End Date
    10/31/2003 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/17/2003 - 20 years ago

Novel Therapies for BioFilm-Related Infections

DESCRIPTION (provided by investigator): Biofilms are surface attached bacterial communities encased in a hydrated matrix of exopolysaccharide. In the body, infecting bacteria form biofilms on medical implants, such as indwelling catheters. In this biofilm mode of growth, they are resistant to antibiotics and attack by the body's immune system. Staphylococcal biofilms are the leading cause of hospital acquired implant-based infections, which result in approximately 30,000 deaths per year. S. epidermidis is the leading cause of these infections. The overall goal of this Fast Track grant is to discover drugs that selectively block the formation of staphylococcal biofilms. These drugs will be used to coat the surfaces of medical implants to prevent biofilm development when implants are placed in patients. Here, in phase I, we will demonstrate the capacity to perform molecular genetic analyses in S. epidermidis; we will develop a cell-based high throughput screen for biofilm development, and we will develop a biofilm reactor system for S. epidermidis. The work in Phase I will provide all the molecular genetic tools and screening methods needed in Phase II for the discovery of potent small molecule inhibitors of staphylococcal biofilm formation.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R44
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    25573
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:25573\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    OSCIENT PHARMACEUTICALS CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    WALTHAM
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    024538443
  • Organization District
    UNITED STATES